📊 RGBPP Key Takeaways
Is Regen BioPharma Inc (RGBPP) a Good Investment?
Regen BioPharma exhibits severe financial distress with negative stockholders' equity of -6.6M, indicating technical insolvency. The company faces an acute liquidity crisis with only 4.6K in cash against 6.8M in liabilities and a current ratio of 0.03x, while continuing to burn 197.9K in operating cash flow with near-zero revenue generation of 59.1K.
Regen BioPharma shows negligible revenue alongside extremely negative margins, deep losses, and a severely impaired balance sheet with negative equity and minimal cash. Liquidity is critically strained (0.03x current/quick) and interest coverage is negative, implying urgent dependence on external financing and high risk of dilution or restructuring.
Why Buy Regen BioPharma Inc Stock? RGBPP Key Strengths
- Minimal revenue base provides potential runway for operational restructuring
- No explicit long-term debt obligations limiting structured default risk
- Small operating cost structure reduces absolute capital requirements for survival
- Some existing (albeit minimal) revenue stream
- Asset-light model with negligible capex needs
- No long-term debt reported
RGBPP Stock Risks: Regen BioPharma Inc Investment Risks
- Negative shareholders' equity of -6.6M indicates technical insolvency and negative book value
- Critical liquidity crisis: 4.6K cash against 6.8M liabilities with 0.03x current ratio suggests imminent solvency risk
- Severe cash burn of 197.9K operating cash flow with stalled revenue at 59.1K (0% YoY growth) creates unsustainable funding gap
- Net losses deteriorating sharply at -967.9K with -90.7% YoY decline indicating worsening operational performance
- No insider activity in past 90 days suggests complete loss of management confidence
- Extreme negative margins (-933.9% operating, -1638.6% net) indicate fundamental business model failure
- Acute liquidity shortfall and going‑concern risk
- Negative equity with liabilities far exceeding assets
- Dependence on external financing leading to dilution or default risk
Key Metrics to Watch
- Cash runway and days of liquidity remaining before insolvency
- Revenue growth rate and product commercialization milestones
- Monthly operating cash burn trend and path to cash flow break-even
- Stockholders' equity trajectory and debt restructuring activities
- Insider transactions as indicator of management confidence
- Quarterly net loss magnitude and operating expense reduction progress
- Cash & Equivalents
- Operating Cash Flow
Regen BioPharma Inc (RGBPP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RGBPP Profit Margin, ROE & Profitability Analysis
RGBPP vs Healthcare Sector: How Regen BioPharma Inc Compares
How Regen BioPharma Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Regen BioPharma Inc Stock Overvalued? RGBPP Valuation Analysis 2026
Based on fundamental analysis, Regen BioPharma Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Regen BioPharma Inc Balance Sheet: RGBPP Debt, Cash & Liquidity
RGBPP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Regen BioPharma Inc's revenue has shown modest growth of 0% over the 5-year period. The most recent EPS of $-0.16 indicates the company is currently unprofitable.
RGBPP Revenue Growth, EPS Growth & YoY Performance
RGBPP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $59.1K | -$515.4K | $-0.01 |
| Q3 2025 | $59.1K | -$130.1K | $-0.01 |
| Q2 2025 | $59.1K | -$19.4K | $0.00 |
| Q1 2025 | $59.1K | -$144.9K | $-0.04 |
| Q3 2024 | $31.6K | -$99.2K | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Regen BioPharma Inc Dividends, Buybacks & Capital Allocation
RGBPP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Regen BioPharma Inc (CIK: 0001589150)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGBPP
What is the AI rating for RGBPP?
Regen BioPharma Inc (RGBPP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGBPP's key strengths?
Claude: Minimal revenue base provides potential runway for operational restructuring. No explicit long-term debt obligations limiting structured default risk. ChatGPT: Some existing (albeit minimal) revenue stream. Asset-light model with negligible capex needs.
What are the risks of investing in RGBPP?
Claude: Negative shareholders' equity of -6.6M indicates technical insolvency and negative book value. Critical liquidity crisis: 4.6K cash against 6.8M liabilities with 0.03x current ratio suggests imminent solvency risk. ChatGPT: Acute liquidity shortfall and going‑concern risk. Negative equity with liabilities far exceeding assets.
What is RGBPP's revenue and growth?
Regen BioPharma Inc reported revenue of $59.1K.
Does RGBPP pay dividends?
Regen BioPharma Inc does not currently pay dividends.
Where can I find RGBPP SEC filings?
Official SEC filings for Regen BioPharma Inc (CIK: 0001589150) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGBPP's EPS?
Regen BioPharma Inc has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RGBPP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Regen BioPharma Inc has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RGBPP stock overvalued or undervalued?
Valuation metrics for RGBPP: ROE of N/A (sector avg: 15%), net margin of -1,638.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RGBPP stock in 2026?
Our dual AI analysis gives Regen BioPharma Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGBPP's free cash flow?
Regen BioPharma Inc's operating cash flow is $-197.9K, with capital expenditures of N/A. FCF margin is -335.1%.
How does RGBPP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,638.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).